Development PipelineDisitamab vedotin

an investigational antibody-drug conjugate directed to HER2

The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Clinical Trials

SGNDV-001: Locally advanced or metastatic urothelial cancer with HER2 expression

ClinicalTrials.Seagen.com ClinicalTrials.gov

Phase 1
Phase 2
Phase 3

RC48 G001: Locally advanced or metastatic urothelial cancer with HER2 expression

ClinicalTrials.Seagen.com ClinicalTrials.gov

Phase 1
Phase 2
Phase 3

SGNDV-005: Locally advanced or metastatic solid tumors with HER2 expression

ClinicalTrials.Seagen.com ClinicalTrials.gov

Phase 1
Phase 2
Phase 3

SGNDV-004: Locally advanced or metastatic breast cancer and gastric cancer with HER2 expression

ClinicalTrials.Seagen.com ClinicalTrials.gov

Phase 1
Phase 2
Phase 3

Program Resources

High-level synopsis of disitamab vedotin and ongoing clinical trials

View/Download

Detailed information about disitamab vedotin clinical trials

View in Interactive Pipeline